Breda, the Netherlands / Ghent, Belgium– arGEN-X N.V. (Euronext Brussels: ARGX), a clinical-stage biopharmaceutical company focused on creating and developing differentiated therapeutic antibodies for the treatment of cancer and severe autoimmune diseases, today announced that Chief Executive Officer, Tim Van Hauwermeiren, will present a corporate update at the Wedbush 2014 Life Sciences Management Access Conference in New York City (NY, USA) on Tuesday, 12 August 2014 at 3:05pm EDT.
arGEN-X to Present at the Wedbush 2014 Life Sciences Management Access Conference
News
August 04, 2014
